Premium
Update on the therapy for myelodysplastic syndrome
Author(s) -
Kasner Margaret T.,
Luger Selina M.
Publication year - 2009
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21352
Subject(s) - myelodysplastic syndromes , medicine , intensive care medicine , hematological disorders , blood cancer , oncology , hematologic neoplasms , palliative care , cancer , bone marrow , nursing
The myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic stem cell disorders characterized by cytopenias. Patients have a risk of developing acute leukemia though most subcome to complications of low blood counts. Over the past decade many novel treatments have been developed and investigation of new agents is ongoing. In this article, we discuss the classification and prognostic systems that are used in MDS, the agents available for treatment of MDS as well as review supportive and palliative care options for patients who are not candidates for, or opt against, newer treatment strategies. Am. J. Hematol. 2009. © 2008 Wiley‐Liss, Inc.